

11 New osteopontin derived chemotactic and inhibitory peptides useful for
12 promoting scarless wound healing, modulating cellular chemotaxis,
13 promoting formation of atherosclerotic plaques and preventing metastasis
14
15 Claim 17: Page 43: 6pp: English.
16
17 The present sequence is an osteopontin derived chemotactic peptide.
18 Such chemotactic peptides are useful for promoting scarless wound
19 healing, modulating chemotaxis and promoting cell migration to a wound
20 site in a cell of a subject. They are also used for modulating cellular
21 chemotaxis in a mammalian cell such as smooth muscle cell, a macrophage,
22 an endothelial cell, a vascular cell and a tumor prone cell. They are
23 useful for treating the formation of atherosclerotic plaques in a
24 subject. The peptides are used for preventing metastasis, treating an
25 atherosclerotic-associated disease such as arthritis, psoriasis, hemodialysis,
26 tumor metastasis or ocular neovascularization. They are also used for
27 activating cell apoptosis, for modulating intracellular production and
28 for reducing chemotaxis. The peptides are useful for chemotaxis, treating
29 and preventing tumor metastasis, inflammation, osteoporosis and immune
30 diseases. They can also be used to enhance an immune response by
31 promoting macrophages.

32 Sequence 4 AA:

33 Query Match 100.00% Score 20; DB 21; Length 11
34 Best Local Similarity 100.00% Prod. No. 6,400,097
35 Matches 4; Conservative 0; Mismatches 0; Gaps 0

36 1 VLEP 4

37 1 VLEP 4

38 RESULT 2

39 AAB29558

40 10 AAB29558 standard; peptide; 4 AA.

41 A AAB29558;

42 14 FEB 2001 (first entry)

43 Adhesion-modulatory peptide, SEQ ID NO:1.

44 Adhesion-modulatory peptide; target cell adhesion; wound healing;
45 endothelial cell; fibroblast; macrophage; neutrophil; megakaryocyte;
46 vascular growth; wound healing; keloid formation; scar tissue; fibrosis;
47 anti-inflammation; anti-inflammation; immunomodulatory; anti-inflammation; anti-inflammation;
48 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
49 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
50 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
51 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
52 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
53 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
54 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
55 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
56 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
57 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
58 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
59 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
60 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
61 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
62 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
63 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
64 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
65 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
66 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
67 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
68 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
69 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
70 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
71 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
72 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
73 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
74 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
75 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
76 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
77 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
78 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
79 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
80 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
81 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
82 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
83 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
84 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
85 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
86 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
87 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
88 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
89 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
90 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
91 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
92 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
93 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
94 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
95 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
96 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
97 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
98 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
99 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
100 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;

61 The invention relates to novel adhesion-modulatory peptides (AAB29558
62 AAB29558) which modulate the adhesion of a target cell to a substrate.
63 The invention also encompasses substrates and devices treated with a
64 peptide of the invention, as well as compositions comprising a peptide of the
65 invention for in vivo use, and analogues, fragments and chemical
66 derivatives of the peptides of the invention. The peptides are used for
67 modulating the adhesion to a substrate of target cells such as
68 endothelial cells, fibroblasts, macrophages, neutrophils or
69 megakaryocytes. The substrate may be a substrate that is found in the
70 body of a patient, e.g., collagen or hyaluronic acid, or may be a
71 synthetic substrate, e.g., a polymeric surface. Titration of LPA, the
72 peptides are useful for regulating vessel growth during wound healing
73 and/or in the treatment of damage resulting from vascular disease, for
74 inhibiting or preventing cellular apoptosis, in the treatment of
75 fibrosis, in particular in the clearing of debris to minimise wound
76 contraction, thereby reducing keloid tissue formation and scarring, and
77 as anti-clotting agents. The peptides also have an immunomodulatory
78 effect, and an anti-thrombotic effect, by adhering to neutrophils.
79 Additionally, peptides of the invention have an anti-tumor effect by
80 competing for alpha 5 beta 1 integrin binding on the cell surface, and an
81 anti-tumorigenic effect by having anti-cp44 activity. The peptides are
82 useful for stimulating and/or enhancing cell attachment to a target
83 scaffold, to enhance tissue growth and for coating medical devices,
84 including prostheses and implants (e.g., vascular implants). The present
85 sequence represents a specifically obtained adhesion-modulatory peptide of
86 the invention.

87 Sequence 4 AA:

88 Query Match 100.00% Score 20; DB 21; Length 11
89 Best Local Similarity 100.00% Prod. No. 6,400,097
90 Matches 4; Conservative 0; Mismatches 0; Gaps 0

91 1 VLEP 4

92 1 VLEP 4

93 RESULT 4

94 AAB29558

95 10 AAB29558 standard; peptide; 4 AA.

96 A AAB29558;

97 14 FEB 2001 (first entry)

98 Adhesion-modulatory peptide, SEQ ID NO:1.

99 Adhesion-modulatory peptide; target cell adhesion; wound healing;
100 endothelial cell; fibroblast; macrophage; neutrophil; megakaryocyte;
101 vascular growth; wound healing; keloid formation; scar tissue; fibrosis;
102 anti-inflammation; anti-inflammation; immunomodulatory; anti-inflammation; anti-inflammation;
103 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
104 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
105 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
106 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
107 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
108 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
109 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
110 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
111 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
112 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
113 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
114 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
115 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
116 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
117 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
118 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
119 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
120 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
121 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
122 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
123 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
124 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
125 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
126 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
127 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
128 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
129 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
130 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
131 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
132 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
133 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
134 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
135 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
136 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
137 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
138 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
139 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
140 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
141 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
142 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
143 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
144 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
145 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
146 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
147 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
148 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
149 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
150 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
151 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
152 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
153 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
154 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
155 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
156 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
157 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
158 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
159 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
160 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
161 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
162 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
163 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
164 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
165 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
166 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
167 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
168 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
169 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
170 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
171 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
172 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
173 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
174 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
175 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
176 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
177 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
178 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
179 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
180 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
181 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
182 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
183 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
184 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
185 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
186 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
187 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
188 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
189 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
190 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
191 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
192 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
193 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
194 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
195 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
196 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
197 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
198 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
199 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;
200 anti-inflammation; anti-inflammation; anti-inflammation; anti-inflammation;

201 Ashkar S;

202 2001-007002/01.

203 New adhesive modulatory peptides useful for modulating cell adhesion
204 target cells such as endothelial cells, fibroblasts, macrophages to
205 substrate such as polyvinyl surfaces, collagen

206 Claim 6: Page 27: 6pp: English.

207 New osteopontin derived chemotactic and inhibitory peptides, used for

the people in a great force would be able to do what the soldiers could not do, and that the troops would be able to do what the soldiers could not do.

the present synthesis. We are grateful to Professor J. H. Goldstein for his interest in this work.

Each student had a personal file with a photograph, a list of interests, and a list of friends. The students were given a choice of three different projects to complete. The first project was to create a poster about the importance of recycling. The second project was to create a poster about the importance of saving water. The third project was to create a poster about the importance of saving energy.

of the body of a support, they are also found in a horizontal position in the thorax in a number of species, and in the abdominal region in some species.

concluded for treating the formation of atypical hyperplasia in the colon. The postbiotics are used for preventing and treating the

and other associated disease such as arthritis, psoriasis, iritis and other manifestations of systemic vasculitis, but none of these

for inducing chemotaxis, the peptides are useful for the study of the role of peptides in the cell response for motility and chemotaxis. For motility the peptides are useful for the study of the role of peptides in the cell response for motility and chemotaxis.

of the patients. They can also be used to enhance an immune response to the virus and are safe for use in immunocompromised patients.

W. J. S. 1991

[illegible]

Mutagenesis	4	Chromosomal integration	14, 15	Miscellaneous	14, 15
-------------	---	-------------------------	--------	---------------	--------

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
8

[illegible][illegible][illegible]

Received 10/2/99; revised manuscript accepted 1/10/00; accepted for publication 1/10/00

$$\text{H}(\text{OH})_2 \rightarrow \text{H}_2\text{O} + \frac{1}{2}\text{O}_2.$$
[illegible]
$$Z = \begin{pmatrix} 1 & 1 & 1 \\ 1 & 1 & 1 \\ 1 & 1 & 1 \end{pmatrix}.$$

XX
NY 10001

$\begin{array}{l} \text{I N V } 0.094 ; \\ \text{I B O U T } 1.796 ; \\ \text{I N V } 0.094 ; \\ \text{I B O U T } 1.796 ; \end{array}$

(A)AHU) A.A.HU K.A.Y. & R.

T.A
XX

[illegible]
$$K_1 = \{1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100\}$$
[illegible]

of kinetic properties of bound and unbound molecules (see, e.g., ref. 3, Awwad, 34). The bounds of the invariant represent the limit of the kinetic response of a population of molecules of a fixed size to the change in the composition representing the N terminus of a polypeptide. The upper

receptor type kinase coupled, represented by AAW and the GPCR (G-protein coupled receptor, also known as 7TM, 7 transmembrane). The proteins of the intracellular domain are located in the cytoplasm.

weight of 2.500 g (plus or minus 0.001 g), and the protein content was 15.000 and 14.8% in the two samples, respectively. The protein is a 100% pure protein.

AA944/29 standard: Peptide: 9 AA.
AA644/29;
AA9N-1996. (first entry)
AA944/29: acetyl coenzyme A carboxylase peptide sequence;
AA944/29: acetyl coenzyme A carboxylase: AcVase; plasmid pK111;
AA944/29: transgenic plant: modified oil content;
AA944/29: polyhydroxyalkanoate polymer: herbicide resistance;
AA944/29: oil crop improvement;
AA944/29: *Brassica oleracea*;
AA944/29: 94524246.A1;
AA944/29: 02-Nov-1995;
AA944/29: 27-Apr-1994; 94W-GB006446;
AA944/29: 27-Apr-1994; 94W-GB00646;
AA944/29: (FNU) ZINSA 135;
AA944/29: (FNU) SWL; Ellersburgh KM; Fother PA; Stables AP;
AA944/29: WPI; 1995 462994/49;
AA944/29: DNA encoding acetyl coenzyme A carboxylase, used for production of transgenic plants with controlled expression of AcVase, e.g., for modification of fatty acid synthesis;
AA944/29: (FNU) SGT; Fig 3; 61pp; English;
AA944/29: Wheat; acetyl coenzyme A carboxylase (AcVase) was partially purified from wheat germ and a dominant 220 kDa band was purified as AcVase by column chromatography and SDS-PAGE. After purification in the gel, the protein was hydrolysed using either proteinase lysate, and resulting peptides were purified by electrophoresis and loaded onto an ABI 477A pulse biped peptide sequencer. Sequence data of 4 peptides (this peptide and peptides AA644/29, AA944/29 and AA944/29) were used to design a K111 deduced amino acid sequence (AA644/29, AA944/29, AA944/29 and AA944/29) so as to add to the K111 gene sequence. After cloning into the K111 vector, the K111 gene was transformed into wheat germ cells to create transgenic plants expressing AcVase. The transgenic plants have a lower or a modified oil level, low regulation of oil synthesis can be used to direct the substrate, acetyl coenzyme A, into synthesis of alternative storage materials (starch, protein or novel polymers such as polyhydroxyalkanoates). Full length AcVase genes can be used to create transgenic plants over-expressing AcVase, and therefore with increased oil content. AcVase over expression in transgenic plants such as wheat, barley, maize and rice, which are normally sensitive to herbicides, results in herbicide resistance. Transgenic plants (dicots are normally resistant to herbicides).

```

Query Match      100.0%   Score 207    184.9%
Best Local Similarity 100.0%   Pred. No. 6,400,000
Matches 4; Conservative 0; Mismatches 0; Lock 12;
                                : Gaps 0;

CY      1 VLEP 4
BU      2 VLEP 5

```

XX	AA07169; standard: peptide; 13 AA;
XX	AA07169;
XX	02-JUL-1999 (first entry)
XX	BIA binding peptide.
XX	Cancer associated antigen diagnosis research treatment human
KW	breast cancer; colon cancer; gastric cancer; renal cancer; lung cancer;
KW	prostate cancer.
XX	Homo sapiens.
XX	W0904265-A2.
PD	28 JAN 1999.
PF	15 JUL 1998; GSW-051479.
PR	22 JUN 1998; GWS-01222.
PR	17 JUL 1997; J70US 0896164.
PR	10 OCT 1997; J70US 0891599.
PR	10 OCT 1997; J70US 0901763.
PR	10 OCT 1997; J70US 0948766.
PR	11 OCT 1997; J73B 0621603.
XX	(GWS) 199613 1NS1 ABPR 4PS.
FF	Chen Y, Gou L, Guo A, O'Hare M, Ohta Y, Old LJ; Pradoschuh W, Sahle H, Seaman MJ, Stockert R; Tureci O;
XX	WP: 1999 12449711.
XX	New isolated cancer associated oncogenic acids and polypeptides - isolated using sera from cancer patients, used to develop products for the diagnosis, monitoring or treatment of cancers
XX	Example 16, Para. 762; 787pp; English.
XX	The invention relates to a method for diagnosing a disorder characterized by expression of a human cancer-associated antigen previously called 11P, a novel acid oncogene (AOG), the method comprises: (A) contacting a biological sample isolated from a subject with an agent that specifically binds to the AAG, an expression product or a fragment of an expressed product complexed with an BIA molecule; and (B) determining the interaction between the agent and the AAG or the expressed product as a determination of the disorder. The products and methods can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of various cancer-associated antigens. The invention provides nucleic acid sequences and encoded polypeptides which are cancer associated antigen precursors expressed in human tissues cancer, renal cancer, colon cancer, gastric cancer, prostate cancer and lung cancer.
XX	G-protein 10 AA;
XX	Query Match Score 27 DB 20 Length 70
XX	Best Local Similarity 100.00 Prod. No. 75
XX	Matches 4 Conservative Mismatches 0 Index 3.34E5

RECEIVED
MAY 17 1977

F 05-FEB-1999; 99AD 0008554;
 G 04-AUG-1999; 99AD 0002014;
 XX
 (CYME) UNIV MEDICORNE,
 (SUN-) CSL LTD,
 (SUN-) COMMERCEPATENT SPT & INT RES AGT,
 (SUN-) COUNTRY ENTERPRISES INC, MEDICAL RES,
 (SUN-) BALLETT MEDICAL RES WALTER & LITTA,
 XX
 LACKSDALE, SOURAVI G, Walker J;
 W 01; 2003 642604/4K;
 XX
 N seq 1 helper cell epitopes derived from canine distemper virus used for preparation of canine vaccines
 XX
 Title 1; Page 28; 54pp; First edn.
 XX
 AAS 76-000801 represent 1 helper cell epitopes, derived from canine distemper virus (CDV). Compositions comprising these 1 cell helper cell epitopes are useful for inducing an immune response in animals. The epitopes are useful as components of animal health products, vaccine compositions, either simply as synthesized peptide based vaccines and as adjuvants to vaccines containing more complex antigens.
 XX
 Sequence 17 AA;
 XX
 Query Match 100.0%; Score 26; Bit 21; Length 17;
 Best Local Similarity 100.0%; Field No. 1; Score 2;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps
 1 VLEP 4
 1111
 1 VLEP 16
 XX
 APPENDIX I
 AAB/mow
 Title AMeas-06 standard; peptide; 17 AA;
 XX
 AAB=066;
 XX
 1-11-2006 (first entry)
 XX
 AAB=066
 Title AMeas-06 sequence of a helper 1 cell epitope from CDV.
 XX
 1 helper cell epitope; CDV; Immune response; canine distemper virus.
 XX
 Canine distemper virus.
 XX
 W 01; 46390-AA;
 N N
 G 04-AUG-2000;
 XX
 07-FEB-2000; 2000W0 AD00070;
 F F
 05-FEB-1999; 99AD 0008554;
 XX
 04-AUG-1999; 99AD 0002014;
 XX
 (CYME) UNIV MEDICORNE,
 (SUN-) CSL LTD,
 (SUN-) COMMERCEPATENT SPT & INT RES AGT,
 (SUN-) COUNTRY ENTERPRISES INC, MEDICAL RES,
 (SUN-) BALLETT MEDICAL RES WALTER & LITTA,
 XX
 LACKSDALE, SOURAVI G, Walker J;
 W 01; 2003 642604/4K;
 XX
 N seq 1 helper cell epitopes derived from canine distemper virus used for preparation of canine vaccines
 XX
 Title 1; Page 28; 54pp; English

CM pre-train: pre-train search, using sw model

Run on: October 28, 2002, 00:11:04 : Search time 10 seconds
(without alignment)

7,576 Million words 447.0/s

Title: US-09-732-411-15

Portect score: 20

Sequence: 1 VLEP 4

Scoring table: BMS0802

Gap 10.0 : Gapext 0.5

Scored: 24429 scaps, 2442504 residues

Total number of hits satisfying chosen parameters: 25/26

Minimum length: 5

Minimum Match: 40

Maximum Match: 100

First 100 hits: 45, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100

Database:

Issued patterns AA:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488

11 1 VIEP 4

US 09 011 940-72
 Sequence 20 Application US/09/01940
 Patent No. 6245431
 GENERAL INFORMATION:

APPLICANT: Leah, Susan

APPLICANT: Zella-Parker, Susan

APPLICANT: Bellis, John I

TITLE: INVENTION: EARLY IDENTIFICATION OF MYOBACTERIAL DISEASES

FILE REFERENCE: NYU 011

REFERENCE: PATENT: 1997 12 31

REFILING DATE: 1997 12 31

PREVIOUS APPLICATION NUMBER: 60/034,003

PREVIOUS FILING DATE: 1996-12-31

NUMBER OF SEQ ID NOS: 106

SEQUENCE: Patent In Ver. 2.1

TYPE: PAT

ORGANISM: Mycobacterium tuberculosis strain H37Rv
 US-09-011-940-72

Query Match

Best Local Similarity 100.00; Score 20; ID 4; Length 19

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0

12 1 VIEP 4

13 1 VIEP 18

RESULT 1

US 09 011 940-72

Sequence 20 Application US/09/01940

Patent No. 5436228

GENERAL INFORMATION:

APPLICANT: Postlethwaite, Arnold E.

APPLICANT: Seyer, Jerome

APPLICANT: Kadi, Andrew

TITLE OF INVENTION: CHEMOTHERAPEUTIC WOUND HEALING PEPTIDES

NUMBER OF SEQUENCES: 20

CORRESPONDENCE ADDRESS:

ADDRESSEE: Scully, Scott, Murphy & Prosser

STREET: 400 Garden City Plaza

CITY: Garden City

STATE: New York

COUNTRY: U.S.A.

ZIP: 11540

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC DOS/MS DOS

SOFTWARE: Patent Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: 09/011,940

FILING DATE:

CLASSIFICATION: 5.00

APPLICANT: Postlethwaite, Arnold E.

APPLICANT: Seyer, Jerome

APPLICANT: Kadi, Andrew

TITLE OF INVENTION: CHEMOTHERAPEUTIC WOUND HEALING PEPTIDES

NUMBER OF SEQUENCES: 20

CORRESPONDENCE ADDRESS:

ADDRESSEE: Scully, Scott, Murphy & Prosser

STREET: 400 Garden City Plaza

CITY: Garden City

STATE: New York

COUNTRY: U.S.A.

ZIP: 11540

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC DOS/MS DOS

SOFTWARE: Patent Release #1.0, Version #1.25

11 1 VIEP 4

12 1 VIEP 7

Query Match

Best Local Similarity 100.00; Score 20; ID 1; Length 25

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0

13 1 VIEP 4

14 1 VIEP 7

RESULT 4

US 09 011 940-72

Sequence 20 Application US/09/01940

Patent No. 624647

GENERAL INFORMATION:

APPLICANT: Postlethwaite, Arnold E.

APPLICANT: Seyer, Jerome

APPLICANT: Kadi, Andrew

TITLE OF INVENTION: CHEMOTHERAPEUTIC WOUND HEALING PEPTIDES

NUMBER OF SEQUENCES: 25

CORRESPONDENCE ADDRESS:

ADDRESSEE: Scully, Scott, Murphy & Prosser

STREET: 400 Garden City Plaza

CITY: Garden City

STATE: New York

COUNTRY: U.S.A.

ZIP: 11540

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC DOS/MS DOS

SOFTWARE: Patent Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: 09/011,940

FILING DATE:

CLASSIFICATION: 5.00

APPLICANT: Postlethwaite, Arnold E.

APPLICANT: Seyer, Jerome

APPLICANT: Kadi, Andrew

TITLE OF INVENTION: CHEMOTHERAPEUTIC WOUND HEALING PEPTIDES

NUMBER OF SEQUENCES: 25

CORRESPONDENCE ADDRESS:

ADDRESSEE: Scully, Scott, Murphy & Prosser

STREET: 400 Garden City Plaza

CITY: Garden City

STATE: New York

COUNTRY: U.S.A.

ZIP: 11540

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC DOS/MS DOS

SOFTWARE: Patent Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: 09/011,940

FILING DATE:

CLASSIFICATION: 5.00

APPLICANT: Postlethwaite, Arnold E.

APPLICANT: Seyer, Jerome

APPLICANT: Kadi, Andrew

TITLE OF INVENTION: CHEMOTHERAPEUTIC WOUND HEALING PEPTIDES

NUMBER OF SEQUENCES: 25

CORRESPONDENCE ADDRESS:

ADDRESSEE: Scully, Scott, Murphy & Prosser

STREET: 400 Garden City Plaza

CITY: Garden City

STATE: New York

COUNTRY: U.S.A.

ZIP: 11540

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC DOS/MS DOS

SOFTWARE: Patent Release #1.0, Version #1.25

1. SERIAL IN: 00411 N;
 2. APT: 01; 01;
 3. APT: 01; 01;
 4. APT: 01; 01;
 5. APT: 01; 01;
 6. APT: 01; 01;
 7. APT: 01; 01;
 8. APT: 01; 01;
 9. APT: 01; 01;
 10. APT: 01; 01;
 11. APT: 01; 01;
 12. APT: 01; 01;
 13. APT: 01; 01;
 14. APT: 01; 01;
 15. APT: 01; 01;
 16. APT: 01; 01;
 17. APT: 01; 01;
 18. APT: 01; 01;
 19. APT: 01; 01;
 20. APT: 01; 01;
 21. APT: 01; 01;
 22. APT: 01; 01;
 23. APT: 01; 01;
 24. APT: 01; 01;
 25. APT: 01; 01;
 26. APT: 01; 01;
 27. APT: 01; 01;
 28. APT: 01; 01;
 29. APT: 01; 01;
 30. APT: 01; 01;
 31. APT: 01; 01;
 32. APT: 01; 01;
 33. APT: 01; 01;
 34. APT: 01; 01;
 35. APT: 01; 01;
 36. APT: 01; 01;
 37. APT: 01; 01;
 38. APT: 01; 01;
 39. APT: 01; 01;
 40. APT: 01; 01;
 41. APT: 01; 01;
 42. APT: 01; 01;
 43. APT: 01; 01;
 44. APT: 01; 01;
 45. APT: 01; 01;
 46. APT: 01; 01;
 47. APT: 01; 01;
 48. APT: 01; 01;
 49. APT: 01; 01;
 50. APT: 01; 01;
 51. APT: 01; 01;
 52. APT: 01; 01;
 53. APT: 01; 01;
 54. APT: 01; 01;
 55. APT: 01; 01;
 56. APT: 01; 01;
 57. APT: 01; 01;
 58. APT: 01; 01;
 59. APT: 01; 01;
 60. APT: 01; 01;
 61. APT: 01; 01;
 62. APT: 01; 01;
 63. APT: 01; 01;
 64. APT: 01; 01;
 65. APT: 01; 01;
 66. APT: 01; 01;
 67. APT: 01; 01;
 68. APT: 01; 01;
 69. APT: 01; 01;
 70. APT: 01; 01;
 71. APT: 01; 01;
 72. APT: 01; 01;
 73. APT: 01; 01;
 74. APT: 01; 01;
 75. APT: 01; 01;
 76. APT: 01; 01;
 77. APT: 01; 01;
 78. APT: 01; 01;
 79. APT: 01; 01;
 80. APT: 01; 01;
 81. APT: 01; 01;
 82. APT: 01; 01;
 83. APT: 01; 01;
 84. APT: 01; 01;
 85. APT: 01; 01;
 86. APT: 01; 01;
 87. APT: 01; 01;
 88. APT: 01; 01;
 89. APT: 01; 01;
 90. APT: 01; 01;
 91. APT: 01; 01;
 92. APT: 01; 01;
 93. APT: 01; 01;
 94. APT: 01; 01;
 95. APT: 01; 01;
 96. APT: 01; 01;
 97. APT: 01; 01;
 98. APT: 01; 01;
 99. APT: 01; 01;
 100. APT: 01; 01;

Category	Match	100,000	Score	200	100,000	Score
First round	Simulbar 1	100,000	100	100,000	100	100
Second round	4	100,000	100	100,000	100	100
Third round	4	100,000	100	100,000	100	100
Fourth round	4	100,000	100	100,000	100	100
Fifth round	4	100,000	100	100,000	100	100
Sixth round	4	100,000	100	100,000	100	100
Seventh round	4	100,000	100	100,000	100	100
Eighth round	4	100,000	100	100,000	100	100
Ninth round	4	100,000	100	100,000	100	100
Tenth round	4	100,000	100	100,000	100	100
Eleventh round	4	100,000	100	100,000	100	100
Twelfth round	4	100,000	100	100,000	100	100
Thirteenth round	4	100,000	100	100,000	100	100
Fourteenth round	4	100,000	100	100,000	100	100
Fifteenth round	4	100,000	100	100,000	100	100
Sixteenth round	4	100,000	100	100,000	100	100
Seventeenth round	4	100,000	100	100,000	100	100
Eighteenth round	4	100,000	100	100,000	100	100
Nineteenth round	4	100,000	100	100,000	100	100
Twentieth round	4	100,000	100	100,000	100	100
Twenty-first round	4	100,000	100	100,000	100	100
Twenty-second round	4	100,000	100	100,000	100	100
Twenty-third round	4	100,000	100	100,000	100	100
Twenty-fourth round	4	100,000	100	100,000	100	100
Twenty-fifth round	4	100,000	100	100,000	100	100
Twenty-sixth round	4	100,000	100	100,000	100	100
Twenty-seventh round	4	100,000	100	100,000	100	100
Twenty-eighth round	4	100,000	100	100,000	100	100
Twenty-ninth round	4	100,000	100	100,000	100	100
Thirtieth round	4	100,000	100	100,000	100	100
Thirty-first round	4	100,000	100	100,000	100	100
Thirty-second round	4	100,000	100	100,000	100	100
Thirty-third round	4	100,000	100	100,000	100	100
Thirty-fourth round	4	100,000	100	100,000	100	100
Thirty-fifth round	4	100,000	100	100,000	100	100
Thirty-sixth round	4	100,000	100	100,000	100	100
Thirty-seventh round	4	100,000	100	100,000	100	100
Thirty-eighth round	4	100,000	100	100,000	100	100
Thirty-ninth round	4	100,000	100	100,000	100	100
Fortieth round	4	100,000	100	100,000	100	100
Forty-first round	4	100,000	100	100,000	100	100
Forty-second round	4	100,000	100	100,000	100	100
Forty-third round	4	100,000	100	100,000	100	100
Forty-fourth round	4	100,000	100	100,000	100	100
Forty-fifth round	4	100,000	100	100,000	100	100
Forty-sixth round	4	100,000	100	100,000	100	100
Forty-seventh round	4	100,000	100	100,000	100	100
Forty-eighth round	4	100,000	100	100,000	100	100
Forty-ninth round	4	100,000	100	100,000	100	100
Fiftieth round	4	100,000	100	100,000	100	100
Fifty-first round	4	100,000	100	100,000	100	100
Fifty-second round	4	100,000	100	100,000	100	100
Fifty-third round	4	100,000				

—

2011.11.2

THE UNIVERSITY OF CHICAGO

© 2004, Apple Computer, Inc. All rights reserved. Learn more at www.apple.com/education.

853346 - 1966 - N - 111 - 171

1. **INTRODUCTION**

APPLIED ANALYTICAL POLYMER SYMPOSIA

APPL. ANAL. 31(1): 1-10, 1989.

APPELLANT: MARIUKI

APPLICANT: ANTHONY M. ...

APPELLANT: LAWRENCE, R.

TABLE 1. *Summary of the 1997-1998 season*

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847

MANAGEMENT

THESE ARE THE NAMES OF THE

2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 2679, 2680, 2681, 26

UNITED NATIONS

[illegible][illegible]

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains. The *Agrobacterium* strains were grown in YEA medium for 24 h at 28°C. The cell concentration was adjusted to 10⁸ cells/ml. The cells were then mixed with the plant tissue and the transformation efficiency was determined. The results are shown as the mean ± SD of three independent experiments. The transformation efficiency was significantly different from the control (p < 0.05).

2000

Symbol	Meaning
\mathbb{R}	Real numbers
\mathbb{C}	Complex numbers
\mathbb{Q}	Rational numbers
\mathbb{Z}	Integers
\mathbb{N}	Natural numbers
\mathbb{P}	Prime numbers
\mathbb{H}	Hyperbolic numbers
\mathbb{O}	Octonions
\mathbb{S}	Symplectic numbers
\mathbb{T}	Ternary numbers
\mathbb{U}	Unitary numbers
\mathbb{V}	Vector numbers
\mathbb{W}	Weyl numbers
\mathbb{X}	Xenon numbers
\mathbb{Y}	Ytterbium numbers
\mathbb{Z}	Zinc numbers
\mathbb{A}	Algebraic numbers
\mathbb{B}	Bernoulli numbers
\mathbb{C}	Catalan numbers
\mathbb{D}	Dedekind numbers
\mathbb{E}	Euler numbers
\mathbb{F}	Fibonacci numbers
\mathbb{G}	Gaussian numbers
\mathbb{H}	Hermite numbers
\mathbb{I}	Idempotent numbers
\mathbb{J}	Jordan numbers
\mathbb{K}	Kronecker numbers
\mathbb{L}	Lagrange numbers
\mathbb{M}	Möbius numbers
\mathbb{N}	Natal numbers
\mathbb{O}	Orbit numbers
\mathbb{P}	Pascal numbers
\mathbb{Q}	Quadratic numbers
\mathbb{R}	Ramanujan numbers
\mathbb{S}	Schroeder numbers
\mathbb{T}	Tetrahedral numbers
\mathbb{U}	Ulam numbers
\mathbb{V}	Vandermonde numbers
\mathbb{W}	Weyl numbers
\mathbb{X}	Xenon numbers
\mathbb{Y}	Ytterbium numbers
\mathbb{Z}	Zinc numbers

Abstract: Attention; Development

1. **Introduction**
 2. **Methodology**
 3. **Results**
 4. **Discussion**
 5. **Conclusion**
 6. **References**
 7. **Appendix**
 8. **Index**
 9. **Table of Contents**
 10. **Figure 1**
 11. **Figure 2**
 12. **Figure 3**
 13. **Figure 4**
 14. **Figure 5**
 15. **Figure 6**
 16. **Figure 7**
 17. **Figure 8**
 18. **Figure 9**
 19. **Figure 10**
 20. **Figure 11**
 21. **Figure 12**
 22. **Figure 13**
 23. **Figure 14**
 24. **Figure 15**
 25. **Figure 16**
 26. **Figure 17**
 27. **Figure 18**
 28. **Figure 19**
 29. **Figure 20**
 30. **Figure 21**
 31. **Figure 22**
 32. **Figure 23**
 33. **Figure 24**
 34. **Figure 25**
 35. **Figure 26**
 36. **Figure 27**
 37. **Figure 28**
 38. **Figure 29**
 39. **Figure 30**
 40. **Figure 31**
 41. **Figure 32**
 42. **Figure 33**
 43. **Figure 34**
 44. **Figure 35**
 45. **Figure 36**
 46. **Figure 37**
 47. **Figure 38**
 48. **Figure 39**
 49. **Figure 40**
 50. **Figure 41**
 51. **Figure 42**
 52. **Figure 43**
 53. **Figure 44**
 54. **Figure 45**
 55. **Figure 46**
 56. **Figure 47**
 57. **Figure 48**
 58. **Figure 49**
 59. **Figure 50**
 60. **Figure 51**
 61. **Figure 52**
 62. **Figure 53**
 63. **Figure 54**
 64. **Figure 55**
 65. **Figure 56**
 66. **Figure 57**
 67. **Figure 58**
 68. **Figure 59**
 69. **Figure 60**
 70. **Figure 61**
 71. **Figure 62**
 72. **Figure 63**
 73. **Figure 64**
 74. **Figure 65**
 75. **Figure 66**
 76. **Figure 67**
 77. **Figure 68**
 78. **Figure 69**
 79. **Figure 70**
 80. **Figure 71**
 81. **Figure 72**
 82. **Figure 73**
 83. **Figure 74**
 84. **Figure 75**
 85. **Figure 76**
 86. **Figure 77**
 87. **Figure 78**
 88. **Figure 79**
 89. **Figure 80**
 90. **Figure 81**
 91. **Figure 82**
 92. **Figure 83**
 93. **Figure 84**
 94. **Figure 85**
 95. **Figure 86**
 96. **Figure 87**
 97. **Figure 88**
 98. **Figure 89**
 99. **Figure 90**
 100. **Figure 91**
 101. **Figure 92**
 102. **Figure 93**
 103. **Figure 94**
 104. **Figure 95**
 105. **Figure 96**
 106. **Figure 97**
 107. **Figure 98**
 108. **Figure 99**
 109. **Figure 100**
 110. **Figure 101**
 111. **Figure 102**
 112. **Figure 103**
 113. **Figure 104**
 114. **Figure 105**
 115. **Figure 106**
 116. **Figure 107**
 117. **Figure 108**
 118. **Figure 109**
 119. **Figure 110**
 120. **Figure 111**
 121. **Figure 112**
 122. **Figure 113**
 123. **Figure 114**
 124. **Figure 115**
 125. **Figure 116**
 126. **Figure 117**
 127. **Figure 118**
 128. **Figure 119**
 129. **Figure 120**
 130. **Figure 121**
 131. **Figure 122**
 132. **Figure 123**
 133. **Figure 124**
 134. **Figure 125**
 135. **Figure 126**
 136. **Figure 127**
 137. **Figure 128**
 138. **Figure 129**
 139. **Figure 130**
 140. **Figure 131**
 141. **Figure 132**
 142. **Figure 133**
 143. **Figure 134**
 144. **Figure 135**
 145. **Figure 136**
 146. **Figure 137**
 147. **Figure 138**
 148. **Figure 139**
 149. **Figure 140**
 150. **Figure 141**
 151. **Figure 142**
 152. **Figure 143**
 153. **Figure 144**
 154. **Figure 145**
 155. **Figure 146**
 156. **Figure 147**
 157. **Figure 148**
 158. **Figure 149**
 159. **Figure 150**
 160. **Figure 151**
 161. **Figure 152**
 162. **Figure 153**
 163. **Figure 154**
 164. **Figure 155**
 165. **Figure 156**
 166. **Figure 157**
 167. **Figure 158**
 168. **Figure 159**
 169. **Figure 160**
 170. **Figure 161**
 171. **Figure 162**
 172. **Figure 163**
 173. **Figure 164**
 174. **Figure 165**
 175. **Figure 166**
 176. **Figure 167**
 177. **Figure 168**
 178. **Figure 169**
 179. **Figure 170**
 180. **Figure 171**
 181. **Figure 172**
 182. **Figure 173**
 183. **Figure 174**
 184. **Figure 175**
 185. **Figure 176**
 186. **Figure 177**
 187. **Figure 178**
 188. **Figure 179**
 189. **Figure 180**
 190. **Figure 181**
 191. **Figure 182**
 192. **Figure 183**
 193. **Figure 184**
 194. **Figure 185**
 195. **Figure 186**
 196. **Figure 187**
 197. **Figure 188**
 198. **Figure 189**
 199. **Figure 190**
 200. **Figure 191**
 201. **Figure 192**
 202. **Figure 193**
 203. **Figure 194**
 204. **Figure 195**
 205. **Figure 196**
 206. **Figure 197**
 207. **Figure 198**
 208. **Figure 199**
 209. **Figure 200**
 210. **Figure 201**
 211. **Figure 202**
 212. **Figure 203**
 213. **Figure 204**
 214. **Figure 205**
 215. **Figure 206**
 216. **Figure 207**
 217. **Figure 208**

2509 4th, 4448 604
Country Martell
100,000; 200,000 148 4; 10,000, 450

Figure 1. Schematic representation of the experimental design. The subjects were divided into two groups: the control group and the experimental group. The control group was divided into two subgroups: the control group and the experimental group. The experimental group was divided into two subgroups: the control group and the experimental group. The control group was divided into two subgroups: the control group and the experimental group. The experimental group was divided into two subgroups: the control group and the experimental group.

— viii —

1. *Introduction*

[illegible][illegible]

Abstract

[illegible][illegible]

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

ACTIVATION NUMBER: 00.00/0.00
 EXPIRATION DATE: 15 SEP 1996
 AGENCY/AGENCY INFORMATION:
 NAME: Mandragoras, Amy E.
 REFERENCE NUMBER: 00.00
 REFERENCE NUMBER: 100-020
 REFERENCE INFORMATION:
 TELEPHONE: (617) 427-7400
 TELEFAX: (617) 427-7400
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 75 amino acids
 TYPE: amino acid
 DRY: 1.00
 MOLECULE TYPE: peptide
 FRAGMENT TYPE: internal
 PS: 0.00/0.00

Query Match: 100.00; Score 20; DB 4; Length 75
 Res. Total Similarity: 100.00; Pred. No. 2,600,000
 Matches: 4; Conservative: 0; Mismatches: 0; Indels: 0; Gaps: 0

1 VLEP 4
 11 25 VLEP 25

Search completed: October 28, 2002, 06:17:41
 2.4 files, 1.4 secs

Genature version 5.1.4
Copyright (c) 1999-2002 Cambridge University

Maximum length: 20
Search time: 06:24:25
Search time: 06:24:25
Search time: 06:24:25

Search time: 06:24:25
Search time: 06:24:25
Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

Search time: 06:24:25

C:Accession: A61300
 C:Field: Y.; Ethna, Y.; Niki, T.; Nakamura, T.; Hekura, A.
 J. Biochem. 92, 1059-1068, 1982
 A:Title: Purification and characterization of a protein from *Escherichia coli* which forms a complex with DNA
 A:Reference number: A61300; MUID:83082696
 A:Accession: A61300
 A:Molecule type: protein
 A:Residues: 1-4 «K18»
 C:Comment: This protein resembles some of the histone like proteins of bacteria in amino acid composition.
 C:Keywords: DNA binding; monomer

Query Match 35.0%; Score 7; DB 2; Length 4;
 Best local Similarity 50.0%; Pred. No. 2.8e+05;
 Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Q7 2 LE 3
 1
 1 ME 2

RESULT 14
 157745
 C:Species: *Escherichia coli* *Escherichia coli*
 C:Date: 07-Jun-1996 #sequence_revision 07 Jun 1996 #text_change 08 Oct 1999
 C:Accession: 157745
 R:Blanco, C.; Ritzenthaler, P.; Kolb, A.
 Mol. Gen. Genet. 202, 112-119, 1986
 A:Title: The regulatory region of the *uxuAB* operon in *Escherichia coli* K12.
 A:Reference number: 157745; MUID:86174344
 A:Accession: 157745
 A>Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-4 «RES»
 A:Accession: U00003411, NID:443300, EIDN:GAA27147.1; FID:Q581254

Query Match 35.0%; Score 7; DB 2; Length 4;
 Best local Similarity 50.0%; Pred. No. 2.8e+05;
 Matches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Q7 2 LE 3
 1
 1 ME 2

RESULT 15
 53508
 C:Title: Starvation-induced ribonuclease - tomato
 C:Species: *Lycopersicon esculentum* (tomato)
 C:Date: 07-Jun-1996 #sequence_revision 07 Jun 1996 #text_change 08 Oct 1999
 C:Accession: S53508
 R:Koeck, M.; Loeffler, A.; Abel, S.; Glund, K.
 Plant Mol. Biol. 27, 477-485, 1995
 A:Title: cDNA structure and regulatory properties of a family of starvation induced ribonucleases
 A:Reference number: S53508; MUID:95201242
 A:Accession: S53508
 A>Status: preliminary
 A:Molecule type: protein
 A:Residues: 1-4 «KOE»

Query Match 35.0%; Score 7; DB 2; Length 4;
 Best local Similarity 100.0%; Pred. No. 2.8e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Q7 4 E 4
 1
 2 E 2

Search completed: October 28, 2002, 06:27:18
 Job time : 50 secs



GENERAL INFORMATION:
 APPLICANT: WONG, POK-TO
 APPLICANT: WONG, SUI-KING
 APPLICANT: KONG, JOHN F.W.
 APPLICANT: KONG, JOHN A.
 APPLICANT: ZHANG, HAN-ZHONG
 TITLE OF INVENTION: FLOW-BLOCKING POLYMER MEMBRANE and
 TITLE OF INVENTION: THE APPLICANTS FOR WHOSE PATENT APPLICATIONS
 TITLE OF INVENTION: SCREENING ASSAYS FOR CUSPIDS AND THE
 TITLE OF INVENTION: USE METHOD
 FILE REFERENCE: 1995-02-0002
 CURRENT APPLICATION NUMBER: 09/441,071
 EARLIER FILING DATE: 1998-10-09
 EARLIER APPLICATION NUMBER: US 09/441,072
 EARLIER FILING DATE: 1997-10-10
 EARLIER APPLICATION NUMBER: US 09/441,073
 EARLIER FILING DATE: 1998-04-04
 NUMBER OF SEQ ID NOS: 142
 SOFTWARE: Patent In Vitro 2.00
 SEQ ID NO 25
 TYPE: PRT
 LENGTH: 4
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Description of Artificial Sequence submitted in
 OTHER INFORMATION: Exports

Query Match: 70.0% Score: 14; Pos: 4; Length: 4;
 Best Local Similarity: 66.7% Prod. No: 1,700,052
 Matches: 23 Conserved Pts: 1; Mismatches: 0; Indels: 0; Gap: 0

25 2 SEP 4
 11
 2 SEP 4

RESULT 13
 US 09 441 071 09
 Sequence 25, Application US/09441071
 Patent No. 646076
 APPLICANT: MATTHEWS, PAUL L.
 APPLICANT: WONG, JOHN A.
 APPLICANT: ZHANG, MARK L.
 TITLE OF INVENTION: Identification of No. 0946076-1 Substrates
 NUMBER OF SEQUENCES: 192
 CORRESPONDENCE ADDRESS:
 ADDRESS: General Co. Inc.
 STREET: 400 Bond St. San Bruno Blvd
 CITY: South San Francisco
 STATE: California
 COUNTRY: USA
 ZIP: 94080
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 5.25 inch 360 Kb floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: MS-DOS/MS-DOS
 SOFTWARE: PatIn (SourceCode)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: 09/441,071
 FILING DATE: 10 MAY 1998
 CLASSIFICATION: 43C
 EARLIER APPLICATION DATA:
 APPLICATION NUMBER: 09/441,072
 FILING DATE: 09 APR 1998
 APPLICATION DATA:
 APPLICATION NUMBER: 09/441,073
 FILING DATE: 10 MAY 1998
 APPLICATION DATA:
 APPLICATION NUMBER: 09/441,074
 FILING DATE: 10 MAY 1998

APPLICATION NUMBER: 09/441,071
 FILING DATE: 09 DEC 1997
 EARLIER APPLICATION DATA:
 APPLICATION NUMBER: 09/441,072
 FILING DATE: 09 AUG 1998
 EARLIER APPLICATION DATA:
 APPLICATION NUMBER: 09/441,073
 FILING DATE: 14 JUN 1998
 EARLIER APPLICATION DATA:
 APPLICATION NUMBER: 09/441,074
 FILING DATE: 10 APR 1998
 EARLIER APPLICATION DATA:
 APPLICATION NUMBER: 09/441,075
 FILING DATE: 09 DEC 1998
 APPLICATION DATA:
 NAME: WONG, JOHN A.
 RESIDUAL NUMBER: 43C 437
 RESIDUAL NUMBER: 646076
 TELEPHONE: 415/273-1249
 TELEFAX: 415/273-1249
 TELE: 910/871 7108
 DIRECTION: 280
 SUBSTANCE CHARACTERISTICS:
 LENGTH: 4 amino acids
 TYPE: amino acid
 Topology: Linear
 US-09-441-071-28

Query Match: 66.0% Score: 13; Pos: 4; Length: 4;
 Best Local Similarity: 66.7% Prod. No: 1,700,052
 Matches: 23 Conserved Pts: 1; Mismatches: 0; Indels: 0; Gap: 0

25 2 SEP 4
 11
 2 SEP 4

RESULT 14
 US 09 441 071 16
 Sequence 13, Application US/09441071
 Patent No. 646076
 GENERAL INFORMATION:
 APPLICANT: Robinson, Keith E.
 APPLICANT: Kapeller, Edith M.
 APPLICANT: White, David
 TITLE OF INVENTION: A No. 0146076-1 Human Cytochrome P-450
 TITLE OF INVENTION: The 4th test case
 FILE REFERENCE: 6800 28
 CURRENT APPLICATION NUMBER: 09/441,071
 EARLIER FILING DATE: 1998-06-11
 EARLIER APPLICATION NUMBER: 09/441,072
 EARLIER FILING DATE: 1998-04-26
 NUMBER OF SEQ ID NOS: 40
 SOFTWARE: Fast Seq for Windows Version 3.1
 SEQ ID NO 16
 LENGTH: 4
 TYPE: PRT
 ORGANISM: Homo sapiens
 US 09 441 071 16
 Query Match: 67.0% Score: 13; Pos: 4; Length: 4;
 Best Local Similarity: 66.0% Prod. No: 1,700,052
 Matches: 23 Conserved Pts: 1; Mismatches: 0; Indels: 0; Gap: 0

25 2 SEP 4
 11
 2 SEP 4

```

1 147000 N 4149876
2 GENERAL INFORMATION:
3 APPLICANT: Red Lion, Keith E.
4 APPLICANT: Kapellier-Libermann, Rosana
5 APPLICANT: White, David
6 TITLE OF INVENTION: A No. 6149876-1 Human Cyclic Nucleosides
7 TITLE OF INVENTION: Phosphodiesterase
8 FILE REFERENCE: 5800-28
9 CURRENT APPLICANT: RIMMER, 09/09/99, 970
10 CURRENT FILING DATE: 1999-06-11
11 EARLIER APPLICATION NUMBER: 09/277,423
12 EARLIER FILING DATE: 1999-04-26
13 NUMBER OF SEQ ID NOS: 40
14 SOFTWARE: FastSeq for Windows Version 3.0
15 SEQ ID NO: 34
16 LENGTH: 4
17 TYPE: CPT
18 ORGANISM: Homo Sapiens
19 147000 N 4149876

```

```

20 100% Match 85.0% Score 143 DB 41 Length 41
21 Best Local Similarity 100.0% Pred. No. 1,700,000
22 Matches 41 Conserved 130 0 Mismatches 0 Gaps 0

```

```

23 1 VIE 3
24 1 VIE 4

```

```

25 147000 N 4149876
26 100% Match 85.0% Score 143 DB 41 Length 41
27 Best Local Similarity 100.0% Pred. No. 1,700,000
28 Matches 41 Conserved 130 0 Mismatches 0 Gaps 0
29 GENERAL INFORMATION:
30 APPLICANT: Coriell, Inc.
31 APPLICANT: Albert C. Gyorkos
32 APPLICANT: Tylo W. Spruce
33 APPLICANT: Axel R. Ismer
34 APPLICANT: John C. Cheronis
35 TITLE OF INVENTION: Serine Protease Inhibitors Comprising
36 TITLE OF INVENTION: Alpha Keto Heterocycles
37 FILE REFERENCE: 061249-006 (21 CIP)
38 CURRENT APPLICANT: RIMMER, 09/09/99, 242
39 CURRENT FILING DATE: 1997-05-20
40 EARLIER APPLICATION NUMBER: US 09/345,820
41 EARLIER FILING DATE: 1996-11-21
42 NUMBER OF SEQ ID NOS: 58
43 SOFTWARE: FastSeq for Windows Version 4.0
44 SEQ ID NO: 41
45 LENGTH: 4
46 TYPE: CPT
47 ORGANISM: Serine Protease
48 147000 N 4149876

```

```

29 100% Match 65.0% Score 143 DB 41 Length 41
30 Best Local Similarity 100.0% Pred. No. 1,700,000
31 Matches 41 Conserved 130 0 Mismatches 0 Gaps 0

```

```

32 1 VIE 3
33 1 VIE 4

```

```

34 Search completed: October 28, 2002, 06:27:54
35 147000 N 4149876

```


SeqWare version 5.1.3
Copyright (c) 1993-2002 Compugen Ltd.

10M protein - protein search, using 82 model

Run on: October 28, 2002, 06:11:34 : Search time 15.35sec/seq
(without optimisations)
25,624 Million cells queried/seq

Library: 03 09 732 411 15

Post-test scores: 20

Sequences: 1 VLEP 4

Sequenced files: R1S096.2

Capsule 100.0 / Capset 0.5

Sequences: 203106 seqs, 6609360 residues

Minimum number of hits satisfying chosen parameters: 1

Maximum hit seq length: 20000000

Post processing: Minimum Match 0.5

Maximum hit seq length: 20000000

Estimated First 45 summaries

Library:

1: p101**

2: p101**

3: p101**

4: p101**

Pred. No. is the number of results predicted by chance. A lower score quoted than or equal to the score of the result tested protein, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	Hit	Accession
1	26	100.0	28	2	AZ261	protease inhibitor
2	26	100.0	47	2	52627	protein p10
3	26	100.0	58	2	S03610	protein p10
4	26	100.0	59	2	R03232	protein p10
5	26	100.0	59	2	A03296	protein p10
6	26	100.0	61	2	104065	protein p10
7	26	100.0	62	2	576471	protein p10
8	26	100.0	63	2	R03062	protein p10
9	26	100.0	68	2	564464	protein p10
10	26	100.0	77	2	572647	protein p10
11	26	100.0	80	2	115290	protein p10
12	26	100.0	85	2	R03234	protein p10
13	26	100.0	82	2	142093	protein p10
14	26	100.0	83	2	119717	protein p10
15	26	100.0	86	2	R03067	protein p10
16	26	100.0	89	2	R02296	protein p10
17	26	100.0	92	2	R03459	protein p10
18	26	100.0	93	2	R03235	protein p10
19	26	100.0	93	2	540656	protein p10
20	26	100.0	93	2	A03023	protein p10
21	26	100.0	93	2	501217	protein p10
22	26	100.0	93	2	R03063	protein p10
23	26	100.0	93	2	572647	protein p10
24	26	100.0	93	2	572647	protein p10
25	26	100.0	93	2	125656	protein p10
26	26	100.0	93	2	572647	protein p10
27	26	100.0	93	2	R03063	protein p10
28	26	100.0	93	2	R03063	protein p10
29	26	100.0	93	2	R03063	protein p10
30	26	100.0	93	2	R03063	protein p10

40	20	100.0	105	2	A01449	hypothetical protein
41	20	100.0	105	2	S03610	hypothetical protein
42	20	100.0	106	2	R03063	conserved hypothetical protein
43	20	100.0	108	2	115153	protein p10
44	20	100.0	108	2	141447	very hypothetical protein
45	20	100.0	109	2	R03063	hypothetical protein
46	20	100.0	111	2	102112	hypothetical protein
47	20	100.0	111	2	R03063	hypothetical protein
48	20	100.0	112	2	R03063	hypothetical protein
49	20	100.0	113	2	100456	hypothetical protein
50	20	100.0	114	2	R03063	hypothetical protein
51	20	100.0	114	2	R03063	hypothetical protein
52	20	100.0	115	2	R03063	hypothetical protein
53	20	100.0	115	2	R03063	hypothetical protein
54	20	100.0	116	1	Q04581	hypothetical protein
55	20	100.0	116	1	Q04581	hypothetical protein

ALIGNMENTS

PEP11 1

AZ261

Protease inhibitor 7 Sea anemone (Steleodactyla sp.) (Fragments)

1: Spectral: Stelodactyla sp. Stelodactyla sp.

Created: 31 Mar 1999 #Sequence revision 41 Mar 1999 #Text change 19 Jan 1999

Accession: AZ261

Model: De Gebauer, E.

Position: 20, 345, 1002

Alignment: Structural: AZ261

Accession: AZ261

Molecule type: protein

Accession: 1 28 -ME3

Query Match

Best Local Similarity: 100.00% Score: 20; 38 2; Length: 28;

Matches: 4; Conservative: 0; Mismatches: 0; Indels: 0; Gaps: 0

QY 1 VLEP 4

DB 4 VLEP 7

RESULT 4

52627

protein p10 - curled leaved tobacco (Trametes)

1: Species: Nicotiana glauca (curled leaved tobacco)

Created: 19 May 1989 #Sequence revision 19 May 1989 #Text change 11 Jan 2000

Accession: 52627

Model: De Gebauer, E.

Position: 20, 345, 1002

Alignment: Structural: AZ261

Accession: AZ261

Molecule type: protein

Accession: 1 28 -ME3

Superfamily: Thaumatin 1

Query Match

Best Local Similarity: 100.00% Score: 2; 38 2; Length: 47;

Matches: 4; Conservative: 0; Mismatches: 0; Indels: 0; Gaps: 0

QY 1 VLEP 4

DB 4 VLEP 7

RESULT 4

52627

protein p10 - curled leaved tobacco (Trametes)

1: Species: Nicotiana glauca (curled leaved tobacco)

Created: 19 May 1989 #Sequence revision 19 May 1989 #Text change 11 Jan 2000

00 This SWISS-Prot entry is copyrighted. It is produced through a collaboration
01 between the Swiss Institute of Bioinformatics and the EMBL outstation
02 at the European Bioinformatics Institute. There are no restrictions on its
03 use by non-profit institutions as long as its content is not modified
04 and this statement is not removed. Usage by and for commercial
05 entities requires a license agreement. (See <http://www.ebi.ac.uk/edl/terms.html>
06 or send an email to license@ebi.ac.uk.)

07 EMBL accession: AAA04341.1; Mol. 1;
08 InterPro: IPR004341; Mol. 1;
09 Pfam PF02411; Mol. 1;
10 KW Transport; Membrane; Monomer; Resistance; Inner membrane; Length 116;
11 Transmem 16; 6; P-TERMINAL;
12 TRANSMEM 44; 6; P-TERMINAL;
13 TRANSMEM 94; 14; P-TERMINAL;
14 METAL 24; 23; HG(25) (BY SIMILARITY);
15 METAL 25; 25; HG(25) (BY SIMILARITY);
16 METAL 76; 76; HG(25) (BY SIMILARITY);
17 METAL 62; 62; HG(25) (BY SIMILARITY);
18 SEQUENCE 116 AA; 12599 MW; AAEL676244BAV33 (res.4);

09 Query Match: 100.00; Score 29; ID 1; Length 116;
10 Best Local Similarity: 100.00; Prod. No. 1; Length 116;
11 Matches: 4; Conservative: 0; Mismatches: 0; Indels: 0; Gaps: 0;
12 1 VIEW 4
13 4 VIEW 4

00 RESULT 1;
01 MERF_PSEF;
02 A: P-4474;
03 01 NOV 1996 (Ref. 95, created)
04 01 NOV 1996 (Ref. 95, last sequence update)
05 01 NOV 1997 (Ref. 95, last annotation update)
06 Mercuric transport protein (Mercury ion transport protein).
07 MERF;
08 Pseudomonas fluorescens;
09 Plasmid pMER427;
10 Bacterial; Proteobacteria; gamma subdivision; Pseudomonadaceae;
11 Pseudomonas;
12 EX NCBI TaxID: 294;
13 FN 111;
14 SEQUENCE FROM N.A.
15 REF: 944132; PubMed 841071;
16 Berman J, Klehman V, Nikitich V, Pridmore P, Strike P,
17 Yurkova O;
18 "The sequence of the mer operon of pMER427 and its transcription ends at
19 pMER427/419, 340 and 955";
20 Gene 146, 74-78 (1994).
21 1. FUNCTION: INVOLVED IN MERUPTIN TRANSPORT. TRANSFER A HYDROLYZIN
22 FROM THE PERIPLASMIC MERF PROTEIN TO THE MEMBRANE PEPTIDASE
23 (MERF).
24 1. SUBCELLULAR LOCATION: Inner membrane; protein membrane;
25 (BY SIMILARITY).

00 This SWISS-Prot entry is copyrighted. It is produced through a collaboration
01 between the Swiss Institute of Bioinformatics and the EMBL outstation
02 at the European Bioinformatics Institute. There are no restrictions on its
03 use by non-profit institutions as long as its content is not modified
04 and this statement is not removed. Usage by and for commercial
05 entities requires a license agreement. (See <http://www.ebi.ac.uk/edl/terms.html>
06 or send an email to license@ebi.ac.uk.)

07 EMBL accession: AAA04341.1; Mol. 1;
08 InterPro: IPR004341; Mol. 1;
09 Pfam PF02411; Mol. 1;
10 KW Transport; Membrane; Monomer; Resistance; Inner membrane; Length 116;
11 Transmem 16; 6; P-TERMINAL;
12 TRANSMEM 44; 6; P-TERMINAL;
13 TRANSMEM 94; 14; P-TERMINAL;
14 METAL 24; 23; HG(25) (BY SIMILARITY);
15 METAL 25; 25; HG(25) (BY SIMILARITY);
16 METAL 76; 76; HG(25) (BY SIMILARITY);
17 METAL 62; 62; HG(25) (BY SIMILARITY);
18 SEQUENCE 116 AA; 12599 MW; AAEL676244BAV33 (res.4);

09 Query Match: 100.00; Score 29; ID 1; Length 116;
10 Best Local Similarity: 100.00; Prod. No. 1; Length 116;
11 Matches: 4; Conservative: 0; Mismatches: 0; Indels: 0; Gaps: 0;
12 1 VIEW 4
13 4 VIEW 4

00 RESULT 1;
01 MERF_PSEF;
02 A: P-4474;
03 01 NOV 1996 (Ref. 95, created)
04 01 NOV 1996 (Ref. 95, last sequence update)
05 01 NOV 1997 (Ref. 95, last annotation update)
06 Mercuric transport protein (Mercury ion transport protein).
07 MERF;
08 Pseudomonas fluorescens;
09 Plasmid pMER427;
10 Bacterial; Proteobacteria; gamma subdivision; Pseudomonadaceae;
11 Pseudomonas;
12 EX NCBI TaxID: 294;
13 FN 111;
14 SEQUENCE FROM N.A.
15 REF: 944132; PubMed 841071;
16 Berman J, Klehman V, Nikitich V, Pridmore P, Strike P,
17 Yurkova O;
18 "The sequence of the mer operon of pMER427 and its transcription ends at
19 pMER427/419, 340 and 955";
20 Gene 146, 74-78 (1994).
21 1. FUNCTION: INVOLVED IN MERUPTIN TRANSPORT. TRANSFER A HYDROLYZIN
22 FROM THE PERIPLASMIC MERF PROTEIN TO THE MEMBRANE PEPTIDASE
23 (MERF).
24 1. SUBCELLULAR LOCATION: Inner membrane; protein membrane;
25 (BY SIMILARITY).

00 This SWISS-Prot entry is copyrighted. It is produced through a collaboration
01 between the Swiss Institute of Bioinformatics and the EMBL outstation
02 at the European Bioinformatics Institute. There are no restrictions on its
03 use by non-profit institutions as long as its content is not modified
04 and this statement is not removed. Usage by and for commercial
05 entities requires a license agreement. (See <http://www.ebi.ac.uk/edl/terms.html>
06 or send an email to license@ebi.ac.uk.)

07 EMBL accession: AAA04341.1; Mol. 1;
08 InterPro: IPR004341; Mol. 1;
09 Pfam PF02411; Mol. 1;
10 KW Transport; Membrane; Monomer; Resistance; Inner membrane; Length 116;
11 Transmem 16; 6; P-TERMINAL;
12 TRANSMEM 44; 6; P-TERMINAL;
13 TRANSMEM 94; 14; P-TERMINAL;
14 METAL 24; 23; HG(25) (BY SIMILARITY);
15 METAL 25; 25; HG(25) (BY SIMILARITY);
16 METAL 76; 76; HG(25) (BY SIMILARITY);
17 METAL 62; 62; HG(25) (BY SIMILARITY);
18 SEQUENCE 116 AA; 12599 MW; AAEL676244BAV33 (res.4);

09 Query Match: 100.00; Score 29; ID 1; Length 116;
10 Best Local Similarity: 100.00; Prod. No. 1; Length 116;
11 Matches: 4; Conservative: 0; Mismatches: 0; Indels: 0; Gaps: 0;
12 1 VIEW 4
13 4 VIEW 4

00 RESULT 1;
01 MERF_PSEF;
02 A: P-4474;
03 01 NOV 1996 (Ref. 95, created)
04 01 NOV 1996 (Ref. 95, last sequence update)
05 01 NOV 1997 (Ref. 95, last annotation update)
06 Mercuric transport protein (Mercury ion transport protein).
07 MERF;
08 Pseudomonas fluorescens;
09 Plasmid pMER427;
10 Bacterial; Proteobacteria; gamma subdivision; Pseudomonadaceae;
11 Pseudomonas;
12 EX NCBI TaxID: 294;
13 FN 111;
14 SEQUENCE FROM N.A.
15 REF: 944132; PubMed 841071;
16 Berman J, Klehman V, Nikitich V, Pridmore P, Strike P,
17 Yurkova O;
18 "The sequence of the mer operon of pMER427 and its transcription ends at
19 pMER427/419, 340 and 955";
20 Gene 146, 74-78 (1994).
21 1. FUNCTION: INVOLVED IN MERUPTIN TRANSPORT. TRANSFER A HYDROLYZIN
22 FROM THE PERIPLASMIC MERF PROTEIN TO THE MEMBRANE PEPTIDASE
23 (MERF).
24 1. SUBCELLULAR LOCATION: Inner membrane; protein membrane;
25 (BY SIMILARITY).

Mat 405 40 Conservative 00 Mismatch 00 1000000 00 00000000

VF 1 VLEB-4

10 40 VLEB-49

Search completed: October 28, 2002, 06:17:21
Data file: 129.secs

Copyright (c) 1993-2002 Computer

CM protein protein search, using SW model

Pub. on: October 26, 2002, 04:11:25 Search time: 0.3 seconds
(with boot alignment)

11/01/02 05:00:00 5.000E+000 5.000E+000 5.000E+000

Best score: 20

Sequence: 1 VIEP-1

Search table: BLAST-2

Search: 0.000E+000 5.000E+000 5.000E+000

Number of hits displayed: 10

Maximum hit length: 200000000

Post processing: Minimum Match ok

Maximum Match: 1000

Database: 1. SP-archived

1. SP-archived

2. SP-archived

3. SP-archived

4. SP-archived

5. SP-archived

6. SP-archived

7. SP-archived

8. SP-archived

9. SP-archived

10. SP-archived

11. SP-archived

12. SP-archived

13. SP-archived

14. SP-archived

15. SP-archived

16. SP-archived

Prod. No. is the number of results predicted by the model. Results are greater than or equal to the score of the result. Results are determined by multiplying the model score by the prod. no.

SUMMARY

Result No.	Score	Match	Length	ID	Accession
1	20	100.0	25	5	Q08655
2	20	100.0	26	5	Q08652
3	20	100.0	30	13	Q08719
4	20	100.0	44	12	Q08656
5	20	100.0	47	8	Q08657
6	20	100.0	47	8	Q08656
7	20	100.0	47	8	Q08656
8	20	100.0	52	8	Q08656
9	20	100.0	52	8	Q08656
10	20	100.0	58	12	Q08656
11	20	100.0	58	12	Q08656
12	20	100.0	61	12	Q08656
13	20	100.0	62	17	Q08656
14	20	100.0	63	17	Q08656
15	20	100.0	63	17	Q08656
16	20	100.0	64	2	Q08656

17	20	100.0	61	5	Q08656
18	20	100.0	68	10	Q08657
19	20	100.0	71	13	Q08657
20	20	100.0	74	11	Q08652
21	20	100.0	77	2	Q08656
22	20	100.0	77	17	Q08656
23	20	100.0	79	11	Q08656
24	20	100.0	80	5	Q08656
25	20	100.0	91	12	Q08656
26	20	100.0	91	17	Q08656
27	20	100.0	92	8	Q08656
28	20	100.0	92	12	Q08656
29	20	100.0	93	5	Q08656
30	20	100.0	96	9	Q08656
31	20	100.0	96	17	Q08656
32	20	100.0	98	13	Q08656
33	20	100.0	98	15	Q08656
34	20	100.0	98	15	Q08656
35	20	100.0	98	15	Q08656
36	20	100.0	98	15	Q08656
37	20	100.0	98	15	Q08656
38	20	100.0	98	15	Q08656
39	20	100.0	98	15	Q08656
40	20	100.0	98	15	Q08656
41	20	100.0	98	15	Q08656
42	20	100.0	98	15	Q08656
43	20	100.0	98	15	Q08656
44	20	100.0	98	15	Q08656
45	20	100.0	98	15	Q08656

ALIGNMENTS

RESULT 1

Q08655 PRELIMINARY: PR1: 25 AA.

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

Q08655: Q08655: (TERMINATED: 17, (Created)

